TY - JOUR
T1 - Probiotics in the management of colonic disorders
AU - Quigley, Eamonn M.M.
PY - 2007/10
Y1 - 2007/10
N2 - Probiotics have been used in humans for almost a century and widely recommended for the treatment of a variety of ills assumed to be of colonic origin, including diarrhea, constipation, bloating, and flatulence. More recently, probiotics have been evaluated in the management of specific colonic disorders such as inflammatory bowel disease, irritable bowel syndrome, and Clostridium difficile colifis. It is evident that no two probiotics are exactly alike; why then should we expect reproducible results from studies that employ different species or strains, variable formulations, and diverse dosing schedules? When probiotics have been studied with the rigor appropriate to a new therapeutic modality, some coherent results have emerged: specific strains are effective in certain diarrheal states, irritable bowel syndrome, ulcerative colitis, and pouchitis, as well as in the prevention of C. difficile-related colifis. Even here, not to mention other colonic disorders, further adequately powered and appropriately designed trials are needed.
AB - Probiotics have been used in humans for almost a century and widely recommended for the treatment of a variety of ills assumed to be of colonic origin, including diarrhea, constipation, bloating, and flatulence. More recently, probiotics have been evaluated in the management of specific colonic disorders such as inflammatory bowel disease, irritable bowel syndrome, and Clostridium difficile colifis. It is evident that no two probiotics are exactly alike; why then should we expect reproducible results from studies that employ different species or strains, variable formulations, and diverse dosing schedules? When probiotics have been studied with the rigor appropriate to a new therapeutic modality, some coherent results have emerged: specific strains are effective in certain diarrheal states, irritable bowel syndrome, ulcerative colitis, and pouchitis, as well as in the prevention of C. difficile-related colifis. Even here, not to mention other colonic disorders, further adequately powered and appropriately designed trials are needed.
UR - http://www.scopus.com/inward/record.url?scp=38849180192&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38849180192&partnerID=8YFLogxK
U2 - 10.1007/s11894-007-0055-7
DO - 10.1007/s11894-007-0055-7
M3 - Review article
C2 - 17991347
AN - SCOPUS:38849180192
SN - 1522-8037
VL - 9
SP - 434
EP - 440
JO - Current Gastroenterology Reports
JF - Current Gastroenterology Reports
IS - 5
ER -